BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 26993042)

  • 1. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
    J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes.
    Liu XL; Ming YN; Zhang JY; Chen XY; Zeng MD; Mao YM
    Exp Mol Med; 2017 Jan; 49(1):e283. PubMed ID: 28082742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
    Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
    Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
    Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
    J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.
    Igreja Sá IC; Tripska K; Hroch M; Hyspler R; Ticha A; Lastuvkova H; Schreiberova J; Dolezelova E; Eissazadeh S; Vitverova B; Najmanova I; Vasinova M; Pericacho M; Micuda S; Nachtigal P
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Pacana T
    Trans Am Clin Climatol Assoc; 2015; 126():271-88. PubMed ID: 26330688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STK25 is a critical determinant in nonalcoholic steatohepatitis.
    Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
    FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
    Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
    J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.